About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | HLA-B*5701 And Hypersensitivity To Abacavir

HLA-B*5701 And Hypersensitivity To Abacavir

NCT00373945·55 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

GlaxoSmithKline

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Subjects with HIV-1 infection with clinically-suspected hypersensitivity to abacavir.
Subjects must provide consent for skin patch testing and pharmacogenetic evaluation.

You may not be if

Women found to be pregnant at baseline.
Subjects with HIV-1 infection who have tolerated abacavir for at least 12 weeks without experiencing hypersensitivity to the drug.

The record

StatusCompleted

PhaseNo phase

Taking part280

StartedAug 2006

UpdatedMay 18, 2009

Conditions

Where55

GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Beverly Hills, California, United States